24/7 MN – (NASDAQ: ANVS) wins FDA approval for late state Parkinson’s candidate. Shares are also up 22% $16.22 this morning on 5100 shares. And closing in on half a million shares in volume
FDA Allows Annovis Bio To Proceed With Phase 3 Study Of Buntanetap In Parkinson's Disease https://www.nasdaq.com/articles/fda-allows-annovis-bio-to-proceed-with-phase-3-study-of-buntanetap-in-parkinsons-disease